Is Nutex Health, Inc. overvalued or undervalued?

As of 4 June 2025, Nutex Health, Inc. has moved from an attractive to a very attractive valuation grade. The company is currently considered undervalued, with a P/E ratio of 5, significantly lower than its peers, such as Aveanna Healthcare Holdings, Inc. with a P/E of 21.61 and The Pennant Group, Inc. at 33.16. Additionally, Nutex's EV to EBITDA stands at 2.82, which is favorable compared to Aveanna's 11.26, indicating a strong relative valuation.
Key financial ratios further support this assessment, with a remarkable ROCE of 128.63% and an ROE of 76.34%, showcasing the company's efficiency in generating returns. Despite recent stock performance showing a decline of 12.65% over the past week, Nutex Health has delivered an impressive YTD return of 268.73%, far exceeding the S&P 500's 2.44%. This combination of strong fundamentals and relative undervaluation suggests that Nutex Health, Inc. presents a compelling investment opportunity.